Perrigo Settles With Cadence Over Ofirmev Generic Plans

Law360, New York (November 28, 2012, 6:11 PM ET) -- Generic-drug maker Perrigo Co. and its subsidiary Paddock Laboratories LLC have entered into a licensing agreement with Cadence Pharmaceuticals Inc., ending a Delaware patent dispute over Paddock's plans to make a generic version of Cadence's Ofirmev brand of injectable acetaminophen, the companies announced Wednesday.

Under the terms of the agreement, Perrigo has been given the exclusive right of first refusal to negotiate an agreement with San Diego-based Cadence to market an authorized generic version of the injectable form of the pain and fever treatment should Cadence...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required